Eurogin is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Informa

Early bird rates available! Secure your pass now!

DISCOVER PASS OPTIONS
Open main menu

The Nordic Session

Wednesday, March 13 • 13.30 - 17.00

Coordinators:
J. Bonde (Denmark) • J. Dillner (Sweden)

The Nordic countries have ambitious cervical cancer elimination strategies backed by strong, comprehensive registers, organised screening and have been early movers on organised vaccination programs and HPV self-sampling for primary screening.

13.30 - 15.00

Part 1 - Next level for HPV vaccine
in the Nordic Countries

This session will provide a comprehensive update on Nordic HPV vaccination, including reports of registry-based assessment of the impact of the HPV vaccinations, how the vaccine is changing clinical management and present data on faster cervical cancer elimination using concomitant HPV vaccination and HPV screening.

Impact of HPV vaccination in Sweden

J. Lei (Sweden)

Impact of HPV vaccination in Denmark

S. Kjaer (Denmark)

Vaccination after treatment for CIN2+

B. Strander (Sweden)

Concomitant vaccination and screening for faster HPV elimination

J. Dillner (Sweden)

Roundtable: What is next in Nordic vaccination?

J. Bonde (Denmark)

15.00 - 15.30

Coffee Break

15.30 - 17.00

Part 2 - Next level for cervical screening
in the Nordic Countries

This session will provide a comprehensive update on Nordic HPV vaccination, including reports of registry-based assessment of the impact of the HPV vaccinations, how the vaccine is changing clinical management and present data on faster cervical cancer elimination using concomitant HPV vaccination and HPV screening.

Nordscreen – an interactive visualisation of screening quality indicators in the Nordic countries

V. M. Partanen (Finland)

How the predictive value of HPV test differs with new infections - implications for design of screening algorithms

B. Engesæter (Norway)

Primary self-sampling in Sweden

M. Elfström (Sweden)

Danish experiences with primary self-sampling

J. Bonde (Denmark)

Nationwide project for outreach to high risk women (long-term non-attenders)

L. S. Arroyo Mühr (Sweden)

Roundtable: Can screening programs adapt fast enough to encompass new technologies?

J. Dillner (Sweden)

Register today

Don't miss out on the the world’s leading international congress on HPV infection and associated cancers. See you in Stockholm, March 13-16, 2024

REGISTER NOW REGISTER NOW

Copyright © 2023. All rights reserved. Informa Markets, a trading division of Informa PLC.